Table 2

Excluded studies with reasons for exclusion.


Reason for exclusion

Bedognetti et al. [23,24]

Study did not evaluate our predefined comparisona

Boccardo et al. [37]

No relevant topicb

Eaton et al. [25]

Only abstract available and data not sufficiently detailed to include in reviewc

Parker et al. [11]

No prostate cancer patients

Serretta et al. [38,39]

Study did not evaluate our predefined comparisond

aTamoxifen 20 mg daily versus tamoxifen 20 mg once weekly; bEvaluation of insulin-like growth factor 1 and binding proteins in prostate cancer; cTamoxifen 20 mg once weekly versus no additional therapy; dTamoxifen 20 mg/daily given at the early onset of gynecomastia (within one month) for a period of one year versus Tamoxifen 10 mg/daily given for one year starting at the bicalutamide prescription.

Kunath et al. BMC Medicine 2012 10:96   doi:10.1186/1741-7015-10-96

Open Data